Cooper Companies (NASDAQ:COO) 주식

Cooper Companies

CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.

Affirm Card

Large Cap

News

Movers

Trading Ideas

AFRM

AZPN

NTNX

PODD

TCOM

VEEV

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 어펌 홀딩스(NASDAQ:AFRM)의 주가는 강력한 4분기 실적과 낙관적인 1분기 가이던스에 따라 36.04% 상승했다. 몇몇 분석가는 주가 전망을 상향 조정했다.

어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)

The Cooper Companies, Inc. - Common Stock

The Cooper Companies Inc

Traeger Inc

Corner Growth Acquisition Corp Ordinary Shares - Class A

Corner Growth Acquisition Corp

Corner Growth Acquisition Corp Units (1 Ord Class A & 1/3 War)

Corner Growth Acquisition Corp Warrants (01/01/2027)

Mr. Cooper Group Inc

Carbios SA

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Holdings Ltd

Australian Oilseeds Holdings Limited - Warrant

Stocks surged Wednesday morning, with major indices poised to snap a two-day losing streak, as cooler-than-expected inflation reinforced expectations for Federal Reserve <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44274165/inflation-cools-more-than-expected-in-february-strengthens-the-case-for-fed-rate-cuts">rate cuts in 2025</a>.
Futures on major U.S. indices rebounded sharply, with the S&amp;P 500 climbing 1.1% by 9:00 a.m. ET, the Nasdaq 100 jumping 1.6%, and the Dow Jones Industrial Average rising 0.8%. 
Small caps, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), were up 1.2%. 
<h2 class="wp-block-heading">Rate Cut Bets Gain Traction</h2>
The latest Consumer Price Index report showed inflation cooling more than anticipated in February. 
Headline CPI eased to 2.8% year-over-year, coming in below the 2.9% forecast, while core CPI, which strips out food and energy prices, slowed to 3.1%, below expectations of 3.2%
The data strengthened the case for monetary easing, pushing traders to fully price in three Federal Reserve rate cuts in 2025, according to the CME FedWatch Tool.
On the Kalshi event-prediction platform, three rate cuts also emerge as the most likely scenario for 2025. 
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXRATECUTCOUNT-25DEC31?color_scheme=light&#038;widget_size=medium&#038;variant=a&#038;ids=KXRATECUTCOUNT-25DEC31-T2&#038;ids=KXRATECUTCOUNT-25DEC31-T3&#038;ids=KXRATECUTCOUNT-25DEC31-T4" width="488px" height="196px" style="border:0"></iframe>
<h2 class="wp-block-heading">Commodities Surge, Bitcoin Nears $84,000</h2>
Commodity markets reacted strongly to the inflation data, with WTI crude oil climbing 1.6% and copper surging 2.7% to its highest level since May 2024. Silver also gained 1%, while natural gas tumbled 4.4%.
In the cryptocurrency space, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.4% to approach $84,000, while altcoins saw notable gains—Cardano jumped 5% to $0.7590, and Solana advanced 3% to $129.
<h3 class="wp-block-heading">Top Market Movers</h3>
Nasdaq 100's top five premarket performers:
<ol start="1">
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) up 11.69%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) up 6.76%</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) up 5.62%</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) up 5.61%</li>
<li>Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) up 4.64%</li>
</ol>
S&amp;P 500's top five premarket performers:
<ol start="1">
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) up 8.34%</li>
<li>Palantir Technologies Inc. up 6.78%</li>
<li>Intel Corp. up 5.64%</li>
<li>Tesla Inc. up 5.57%</li>
<li>The Cooper Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) up 5.52%</li>
</ol>
Dow Jones' top five premarket performers:
<ol start="1">
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) up 4.51%</li>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) up 2.24%</li>
<li>The Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) up 2.08%</li>
<li>Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) up 2.04%</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) up 1.75%</li>
</ol>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">Trump&#8217;s 25% Tariffs On Steel And Aluminum Imports Take Effect, EU Retaliates: US Steel, Nucor, Century Aluminum And Other Domestic Stocks Cheer</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

AMZN

INTC

MRVL

NVDA

PLTR

SMCI

TSLA

Wall Street Rockets As February Inflation Cools More Than Expected

During the last three months, 5 analysts shared their evaluations of Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Cooper Companies, presenting an average target of $109.4, a high estimate of $115.00, and a low estimate of $105.00. Experiencing a 6.81% decline, the current average is now lower than the previous average price target of $117.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1741381355_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Cooper Companies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$107.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Cooper Companies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cooper Companies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>Discovering Cooper Companies: A Closer Look</h2>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Unraveling the Financial Story of Cooper Companies</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Cooper Companies's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 9.85%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Cooper Companies's net margin excels beyond industry benchmarks, reaching 11.54%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.47%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cooper Companies's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cooper Companies's debt-to-equity ratio is below the industry average at 0.32, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Cooper Companies: 5 Analysts Share Their Views

Stifel analyst Jonathan Block maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Buy and lowers the price target from $115 to $105.

Price Target

Stifel Maintains Buy on Cooper Companies, Lowers Price Target to $105

JP Morgan analyst Robbie Marcus maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Overweight and lowers the price target from $120 to $110.

JP Morgan Maintains Overweight on Cooper Companies, Lowers Price Target to $110

Piper Sandler analyst Jason Bednar reiterates Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Overweight and lowers the price target from $120 to $115.

Reiteration

Piper Sandler Reiterates Overweight on Cooper Companies, Lowers Price Target to $115

WIIM

Cooper Companies shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Citigroup analyst Joanne Wuensch maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Buy and lowers the price target from $115 to $110.

Citigroup Maintains Buy on Cooper Companies, Lowers Price Target to $110

Baird analyst Jeff Johnson maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Outperform and lowers the price target from $117 to $107.

Baird Maintains Outperform on Cooper Companies, Lowers Price Target to $107

Needham analyst David Saxon reiterates Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) from Hold to Hold.

Needham Reiterates Hold on Cooper Companiesto Hold

Guidance

Cooper Companies Sees FY25 Adj. EPS $3.94-$4.02 Vs $3.98 Est.; Revenue $4.080B-$4.158B Vs $4.121B Est.

Cooper Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.91 by 1.1 percent. This is a 8.24 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $964.700 million which missed the analyst consensus estimate of $978.091 million by 1.37 percent. This is a 3.55 percent increase over sales of $931.600 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cooper Companies Q1 2025 Adj. EPS $0.92 Beats $0.91 Estimate, Sales $964.700M Miss $978.091M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $227.93 million. 
• KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $28.12 million. 
• Dingdong (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $793.81 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $40.15 million. 
• Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $38.34 million. 
• ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) is likely to report earnings for its fourth quarter. 
• Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is expected to report quarterly loss at $0.02 per share on revenue of $100.41 million. 
• VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is likely to report quarterly loss at $0.04 per share on revenue of $8.21 million. 
• Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $60.00 million. 
• Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $352.00 million. 
• Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) is projected to report quarterly loss at $1.07 per share on revenue of $26.04 million. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) is likely to report earnings for its third quarter. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $401.10 million. 
• Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $102.27 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $1.91 per share on revenue of $7.84 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report quarterly earnings at $3.76 per share on revenue of $3.29 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $34.87 billion. 
• Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) is projected to report earnings for its fourth quarter. 
• JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $45.16 billion. 
• Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $12.42 million. 
• Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $836.96 million. 
• GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.29 billion. 
• Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is expected to report quarterly loss at $0.60 per share on revenue of $300.28 million. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is expected to report quarterly loss at $0.73 per share on revenue of $3.62 million. 
• Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $370.82 million. 
• ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is likely to report quarterly loss at $0.23 per share on revenue of $498.50 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $1.01 billion. 
• Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) is projected to report earnings for its fourth quarter. 
• Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is projected to report earnings for its fourth quarter. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.95 billion. 
• America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $273.39 million. 
• BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is projected to report quarterly loss at $0.26 per share on revenue of $34.23 million. 
• Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $463.80 million. 
• Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $98.75 million. 
• Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) is expected to report quarterly loss at $0.15 per share on revenue of $634.04 million. 
• Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $8.90 billion. 
• Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $282.20 million. 
• Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $203.10 million. 
• TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $280.86 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $5.30 billion. 
<h3>Companies Reporting After The Bell</h3>
• Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $335.35 million. 
• Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $6.48 million. 
• DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $431.00 million. 
• Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) is projected to report earnings for its fourth quarter. 
• Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $2.37 million. 
• Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is expected to report earnings for its fourth quarter. 
• Silvercrest Asset Mgmt Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $31.97 million. 
• Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is projected to report quarterly loss at $0.02 per share on revenue of $31.80 million. 
• Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) is likely to report earnings for its fourth quarter. 
• ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $717.27 million. 
• Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is projected to report quarterly loss at $0.20 per share on revenue of $700 thousand. 
• Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is likely to report quarterly loss at $0.02 per share on revenue of $12.01 million. 
• GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is likely to report quarterly loss at $0.03 per share on revenue of $49.77 million. 
• CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.53 million. 
• Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) is estimated to report earnings for its fourth quarter. 
• National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $83.72 million. 
• Fidus Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDUS#NASDAQ">FDUS</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $36.66 million. 
• Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is estimated to report quarterly loss at $1.61 per share on revenue of $5.00 million. 
• IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is expected to report earnings for its second quarter. 
• Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $119.46 million. 
• Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $45.92 million. 
• Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is expected to report quarterly loss at $0.13 per share on revenue of $254 thousand. 
• Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $69.03 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $285.83 million. 
• Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) is likely to report quarterly loss at $0.25 per share on revenue of $6.40 million. 
• MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $78.53 million. 
• Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $30.82 million. 
• BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) is projected to report quarterly loss at $0.05 per share on revenue of $54.17 million. 
• Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $164.62 million. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is projected to report quarterly loss at $0.16 per share on revenue of $78.00 million. 
• AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $91.78 million. 
• Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $272.74 million. 
• Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is expected to report quarterly loss at $0.02 per share on revenue of $37.96 million. 
• a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) is projected to report quarterly loss at $0.23 per share on revenue of $154.49 million. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $56.78 million. 
• Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $285.79 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $3.95 million. 
• American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $161.78 million. 
• El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $115.83 million. 
• Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) is likely to report quarterly loss at $0.14 per share on revenue of $121.36 million. 
• Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $115.23 million. 
• Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $221.13 million. 
• Granite Ridge Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNT#NYSE">GRNT</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $104.93 million. 
• Invesco Dorsey Wright Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is likely to report quarterly loss at $0.47 per share on revenue of $5.92 million. 
• Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is expected to report quarterly loss at $0.34 per share on revenue of $5.92 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $4.07 billion. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $7.82 billion. 
• HASHICORP INC CL A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $175.71 million. 
• ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $7.38 million. 
• Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $57.62 million. 
• Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.19 per share on revenue of $75.78 million. 
• Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $145.00 million. 
• Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is expected to report quarterly earnings at $1.47 per share on revenue of $14.62 billion. 
• Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is estimated to report earnings for its fourth quarter. 
• Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $42.70 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $980.87 million. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.01 per share on revenue of $62.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

ACDC

ALXO

AOUT

APEI

ARCT

ASLE

ASUR

AVGO

AVIR

BBAI

BlackSky Technology Inc. Class A Common Stock

BKSY

BTSG

BURL

CANG

CBRL

CHMI

CLAR

COOK

COST

CRMT

CTMX

DCTH

DLNG

DOMO

DSGR

DXPE

ELUT

EVGN

FDUS

FNKO

GENK

GEVO

GHLD

GRNT

GWRE

HDSN

HIPO

KVHI

LOCO

LODE

LOMA

LXRX

MCHX

MLNK

MNMD

MODV

MOLN

NCMI

NDLS

PACK

PBPB

PHAT

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTH

PSNY

REAX

REFR

RELI

SAMG

SERV

SHIP

STVN

SUNS

SWBI

TRMD

VRME

WLDN

WLYB

XERS

XTNT

Earnings Scheduled For March 6, 2025

Disclosed in a recent SEC filing on December 12, III, President &amp; CEO at Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: III, President &amp; CEO at Cooper Companies, made a strategic move by exercising stock options for 0 shares of COO as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000711404/000156218024008371//Archives/edgar/data/711404/000156218024008371/0001562180-24-008371-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $0.
During Friday's morning session, Cooper Companies shares down by 0.34%, currently priced at $96.39. Considering the current price, III's 0 shares have a total value of $0.
<h3>Delving into Cooper Companies's Background</h3>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Cooper Companies: Financial Performance Dissected</h3>
Revenue Growth: Cooper Companies's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 9.85%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 66.55%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Cooper Companies's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.588677.
</li>
</ul>
Debt Management: Cooper Companies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 49.35 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.98 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 20.32, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000711404">Check Out The Full List Of Cooper Companies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Exercise Activity Initiated By White Albert G III At Cooper Companies

Disclosed in a recent SEC filing on December 12, G, EVP at Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: The latest Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000711404/000156218024008373//Archives/edgar/data/711404/000156218024008373/0001562180-24-008373-index.htm">U.S. Securities and Exchange Commission</a> uncovered G, EVP at Cooper Companies, exercising stock options for 0 shares of COO. The total transaction was valued at $0.
Cooper Companies shares are trading, exhibiting down of 0.34% and priced at $96.39 during Friday's morning. This values G's 0 shares at $0.
<h3>All You Need to Know About Cooper Companies</h3>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Unraveling the Financial Story of Cooper Companies</h3>
Positive Revenue Trend: Examining Cooper Companies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.85% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 66.55%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Cooper Companies's EPS is below the industry average. The company faced challenges with a current EPS of 0.588677. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Cooper Companies's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 49.35 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 4.98, Cooper Companies's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 20.32 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000711404">Check Out The Full List Of Cooper Companies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise Update At Cooper Companies: Andrews Brian G Engages

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is one of his <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">&#8220;least favorite oils.&#8221;</a>
On Monday, UBS analyst Josh Silverstein maintained Occidental Petroleum with a Neutral and lowered the price target from&nbsp;$58&nbsp;to&nbsp;$51, while Wells Fargo analyst Roger Read maintained the stock with an Equal-Weight and cut the price target from&nbsp;$56&nbsp;to&nbsp;$53.
&#8220;I think it's a very good situation,&#8221; Cramer said when asked about The Cooper Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>).
<ul>
<li><a href="https://analytics.google.com/analytics/web/#/p283071105/reports/explorer?params=_u..nav%3Dmaui%26_r..dataFilters%3D%5B%7B%22type%22:1,%22fieldName%22:%22landingPage%22,%22evaluationType%22:4,%22expressionList%22:%5B%22%252Ftrading-ideas%252Flong-ideas%252F24%252F04%252F38312296%252Fjim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro%22%5D,%22complement%22:false,%22isCaseSensitive%22:true,%22expression%22:%22%22%7D%5D&amp;r=6342961161&amp;ruid=all-pages-and-screens,life-cycle,engagement&amp;collectionId=6114769606" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38312296/jim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro">Jim Cramer Recommends Buying Ethereum Or Bitcoin Instead Of This Stock: &#8216;Let&#8217;s Not Fool Around</a>
Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is the &#8220;ultimate speculative, and as long as you know that, then I'm absolutely fine with it,&#8221; Cramer said.
Cramer recommended to keep owning Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and also recommended buying more in case it goes down.
The Mad Money host said he likes Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>). &#8220;I think that their legal stuff is really largely behind them,&#8221; he added.
When asked about Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), he said, &#8220;It's a good situation.&#8221;
As for Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>), the company &#8220;missed the numbers by a mile,&#8221; Cramer said. &#8220;And when I see that, that often means that the next numbers' going to be missed too. So let's be careful there.&#8221;
Price Action:
<ul>
<li>Occidental Petroleum shares fell 0.9% to settle at $48.05 on Tuesday.</li>
<li>Cooper Companies shares fell 0.2% to close at $99.08.</li>
<li>Energy Transfer shares slipped 0.5% to settle at $18.74 on Tuesday.</li>
<li>Abbott shares gained 0.5% to $115.50 on Tuesday.</li>
<li>Kinder Morgan shares fell 0.8% to close at $26.89 on Tuesday.</li>
<li>Advanced Drainage Systems shares fell 1.7% to settle at $128.24 during the session.</li>
<li>Archer Aviation shares slipped 1.3% to close at $7.72 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

ACHR

Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $109.75, a high estimate of $118.00, and a low estimate of $102.00. Marking an increase of 2.09%, the current average surpasses the previous average price target of $107.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733515264_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cooper Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cooper Companies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cooper Companies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>Delving into Cooper Companies's Background</h2>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Key Indicators: Cooper Companies's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Cooper Companies's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 7.8%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Cooper Companies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.44% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cooper Companies's ROA stands out, surpassing industry averages. With an impressive ROA of 0.87%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.33, Cooper Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Cooper Companies

Citigroup analyst Joanne Wuensch maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Buy and lowers the price target from $116 to $115.

Citigroup Maintains Buy on Cooper Companies, Lowers Price Target to $115

The Cooper Companies shares are trading lower. Morgan Stanley cut its price target on the stock from $104 to $102.

Morgan Stanley analyst Patrick Wood maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Equal-Weight and lowers the price target from $104 to $102.

Morgan Stanley Maintains Equal-Weight on Cooper Companies, Lowers Price Target to $102

Press Releases

CooperSurgical Launches Paragard® Intrauterine Copper Contraceptive with New Single-Hand Inserter

CooperCompanies Recognized as a Best Workplace for Innovators

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2024

CooperCompanies Announces Fourth Quarter and Full Year 2024 Results

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies Announces Release Date for First Quarter 2025

CooperCompanies Announces First Quarter 2025 Results

The Wyatt Foundation and The Conceive Fertility Foundation Announce Launch of 2025 IVF Grant Program

Comments

Cooper Companies

뉴스

파트너 / 기고자

벤징가 글로벌